A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension

Study Summary

The primary objective of this study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in participants with pulmonary arterial hypertension (PAH).

Conditions

Pulmonary Arterial Hypertension

Interventions / Drugs

Parenteral Treprostinil Oral Treprostinil

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment52 participants

Primary Completion—

Lead SponsorUnited Therapeutics

Data Retrieved2026-04-11 04:30:42.432898+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.